Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Post-authorisation Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto Rm) for the Prevention of Stroke in Patients with AF, Treatment of DVT and PE, and the Prevention of Recurrent DVT and PE in the Secondary Care Hospital Setting in England and Wales

Next Previous
X
Search
Trial Profile

An Observational Post-authorisation Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto Rm) for the Prevention of Stroke in Patients with AF, Treatment of DVT and PE, and the Prevention of Recurrent DVT and PE in the Secondary Care Hospital Setting in England and Wales

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Sep 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Anticoagulants
  • Indications Deep vein thrombosis; Pulmonary embolism; Stroke
  • Focus Adverse reactions
  • Acronyms ROSE

    • Most Recent Events

    • 26 Aug 2018 Results (n=965) assessing starting dose amongst patients with chronic kidney stage 3 -4 or 5 presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
    • 26 Aug 2018 Results (n=965) presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
    • 26 Aug 2018 Results (n=2542) presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top